Moleac launches CognivAiD™, a novel targeted product for vascular dementia
-
CognivAiD showed clinically significant and clinically meaningful benefits in disease-modifying trials based upon VaDAS-Cog scales and ADCS-CGIC, and a favorable safety profile.
-
CognivAiD has a unique ‘multimodal mechanism of action’, reinforcing Moleac’s dedication to developing scientifically proven innovative formulations for patients with neurological conditions.
SINGAPORE – Jan. 16, 2023 (GLOBE NETWORKWIRE) — Moleac’s announcement on 29Th October 2022 the launch of CognivAiD™, the first-in-market specific product for Vascular Dementia (VaD). An optimized formulation of active extracts from Gingko, Ginseng and Saffron, CognivAiD shows significant and clinically meaningful disease-modifying benefits in patients with VaD, a condition with no targeted treatment at present.
David Picard, CEO of Moleac, commented on the launch: “Moleac focuses on neurology to help patients reconnect with their lives. We have created a unique platform over the last 20 years to bring patients new medicines that meet their neurology needs. This was done with our flagship product NeuroAiD™II, which currently benefits patients from over 35 countries. We are now leveraging our infrastructure, expertise and partners to offer more treatments to patients suffering from brain dysfunction. We are very proud to launch CognivAiD which fills a big gap in the treatment of vascular dementia and the cognitive disorders it causes.”
Globally, more than 55 million people are living with dementia. There is an average of 10 million cases per year. This is a major financial and economic burden. The global annual cost of dementia is US$1.3 trillion. By 2030, it will rise to US$2.8 Trillion.1. Vascular dementia, the second most common subtype of dementia after Alzheimer’s disease, accounts for 15-30% of all dementia cases2.
VaD is currently being treated with acetylcholinesterase inhibitors (AChE inhibitors), such as donepezil. Also, NMDA antagonists like memantine are available. These options don’t target VaD’s key mechanisms.
“There are currently very few therapeutic options available for patients with VaD. There are very few options available for patients with VaD. The benefits they have are modest and may cause side effects. CognivAiD has been developed through years of research both in the laboratory and in clinical trials. It is a new therapy option that slows down the cognitive decline in patients with VaD and allows them to continue to live their normal lives. Through its properties of vascular protection and vasoregulation as well as modulation of neuroinflammation, it targets complex diseases such VaD. In peer-reviewed journals, rigorous clinical trials have proven its safety and efficacy. We are proud at Moleac to provide access to CognivAiD, a new safe and effective treatment that will benefit VaD patients and their caregivers,” said Dr. Sylvain Durrleman, Head of Medical Affairs at Moleac.
Visit www.amazon.com for more information www.cognivaid.com.
About CognivAiD™
CognivAiD is an evidence-based formulation comprising active extracts from Croci Stigma, Ginkgo Folium and Ginseng Radix et Rhizoma which has been shown to be safe and effective for the treatment of vascular dementia.
About Moleac
Moleac, a biopharmaceutical firm, is dedicated to helping families and patients re-connect with their lives. Based in Singapore, Moleac is a biopharmaceutical company that focuses on developing innovative formulations based on scientific research to address unmet medical needs for patients with neurological conditions like stroke, traumatic brain injuries, dementia, and other neurological conditions.
Moleac’s flagship product NeuroAiD™II reaches more than 30,000 patients in over 35 countries every year. CognivAiD™, the company’s new product for vascular dementia, was launched in October 2022.
Visit this site for more information www.moleac.com.
Clement Dif, Name of Press Contact
Phone: +65 6211 3710
Email: [email protected]
